Maidstone Life Sciences Conference

Events

12th Annual Cancer Immunotherapy Conference

Hosted by MaidStone Life Sciences and William Blair & Company

Tuesday and Wednesday July 12 - 13th

MaidStone Life Sciences and William Blair Biotech Focus Conference

 

Day One

12th Annual Cancer Immunotherapy Conference

8:00 a.m.

 Keynote I: Physicians View of the Challenges and Unmet Needs in Cell Therapies
Matthew Frigault, M.D.
Administrative Director, Cellular Therapy Service
Assistant Professor of Medicine, Harvard Medical School

8:30 a.m.

 Q&A

8:45 a.m.

 Break

8:55 a.m.

 Panel I: Preparing for Launch: Navigating the Regulatory Landscape and Operationalizing Cell Therapies
(Raj moderating)Participating Companies:
Allogene Therapeutics, Inc. (ALLO)
Eric Schmidt, Ph.D.
CFOAutolus Therapeutics, Ltd. (AUTL)
Christian Itin, Ph.D.
CEOArcellx, Inc. (ACLX)
Rami Elghandour
CEOObsidian Therapeutics (private)
Paul Wotton, Ph.D.
CEOAffini-T Therapeutics, Inc. (private)
Jak Knowles, M.D.
Co-founder, President & CEO

10:15 a.m.

Break

10:25 a.m.

 Keynote II: Engineering T-Cells for Enhanced Immunotherapy of Solid Tumors

Michael C. Milone, M.D., Ph.D.
Assistant Professor of Pathology and Laboratory Medicine at the Hospital of University of Pennsylvania
Associate Director, Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine

10:55 a.m.

Q&A

11:05 a.m.

Break

11:15 a.m.

 Panel II: Off The shelf: Next-Generation Allogeneic Cell Therapies
(Sami Moderating)Participating Companies:
Nkarta, Inc. (NKTX)
Paul Hastings
CEOPoseida Therapeutics, Inc. (PSTX)
Mark Gergen
CEOWugen, Inc. (private)
Dan Kemp, Ph.D.
CEOCentury Therapeutics, Inc. (IPSC)
Lalo Flores, Ph.D.
CEOBeam Therapeutics, Inc. (BEAM)
John Evans
CEO

12:15 p.m.

Lunch

1:00 p.m.

.

 Keynote III: Multispecific Protein Therapies: Where we’ve Been and Where We’re Going?
Patrick Baeuerle, Ph.D.,
Co-founder and Acting Chief Scientific Officer
Cullinan Oncology
Executive Partner, MPM Capital

1:30 p.m.

Q&A

1:40 p.m.

Break

1:50 p.m.

 

 Panel III: Moving Beyond Monoclonals:
The Potential of Multispecific Therapies
(Phipps moderating)Participating Companies:
Immunocore Holdings Plc (IMCR)
Bahija Jallal,
Ph.D.
CEOMerus N.V. (MRUS)
Bill Lundberg, M.D.
CEO, Principal Financial OfficerPieris Pharmaceuticals, Inc. (PIRS)
Steve Yoder
CEOTRIO Pharmaceuticals, Inc. (private)
Reiner Laus,
M.D.
CEO and Co-founder

3:10 p.m.

Break

3:20 p.m.

 Keynote IV: Clinical Trial Considerations for Biology Informed Immuno-Oncology Drug Development
TBD

3:50 p.m.

Q&A

4:00 p.m.

Break

4:10 p.m.

 Panel IV: Developing Therapies for the Next Immuno-Oncology Targets

(Phipps moderating)

Participating Companies:

Agenus, Inc. (AGEN)
Steven O’Day, M.D.
CMO

Codiak BioSciences, Inc. (CDAK)
Doug Williams, Ph.D.,
CEO

Tempest Therapeutics, Inc. (TPST)
Tom Dubensky, Ph.D.,
President

Hibercell, Inc. (private)
Alan Rigby,
Ph.D.
President & CEO

5:20 p.m.

 Closing Remarks

 

Day Two

Key Topics in Biotech 

 

Panel Discussions

 

9:00 a.m.

 Panel 1: Next Generation Small Molecules in Oncology

Ikena Oncology, Inc. (IKNA)
Mark Manfredi, Ph.D.
President & CEO

Kinnate Biopharma, Inc. (KNTE)
Nima Farzan
CEO

Immuneering Corp. (IMRX)
Benjamin Zeskind, Ph.D.
Co-Founder, President and CEO

 

 

9:45 a.m.

Break

10:00 a.m.

 Panel 2: AAV Gene Therapy: Delivery and Beyond

Taysha Gene Therapies, Inc. (TSHA)
RA Session II
President, Founder & CEO

Renovacor, Inc. (RCOR)
Magdalene Cook, Ph.D.
President & Chief Executive Officer

 

10:45 a.m.

Break

11:00 a.m.

 Panel 3: Developing Therapies Against Novel Targets in Autoimmune Diseases

Kezar Life Sciences, Inc (KZR)
Noreen Roth Henig, M.D.,
CMO

Aclaris Therapeutics, Inc. (ACRS)
Neal Walker, D.O.
President & CEO

Nimbus Therapeutics (Private)
Jeb Keiper
Chief Executive Officer

Ventus Therapeutics, Inc. (Private)
Michael Crackower, Ph.D.,
CSO

 

 

 

11:45 a.m.

Break

12:00 p.m.

 Panel 4: Unmet Needs and Novel Therapies in Neuropsychiatry

Axsome Therapeutics, Inc. (AXSM)

Herriot Tabuteau,
MD
CEO

VistaGen Therapeutics, Inc. (VTGN)
Shawn Singh, J.D.
CEO

Bionomics Limited (BNOX)
Errol De Souza, Ph.D.
Executive Chairman

 

12:45 p.m.

Break

1:00 p.m.

 Panel 5: There And Back Again, Dawn Of A New Era in RadiopharmaceuticalsPoint Biopharma Global Inc.
Joe McCann, Ph.D.
President & CEOFusion Pharmaceuticals Inc.
John Valliant, Ph.D.
Founder & CEO

Aktis Oncology, Inc.
Matthew Roden, Ph.D.
President & CEO

Telix Pharmaceuticals Ltd.
Chris Behrenbruch, DPhil, J.D., MBA
Group Managing Director and CEO

 

1:45 p.m.

Break 

2:00 p.m.

 Panel 6: Novel Modalities and Delivery for RNA-Targeted Therapeutics

Ionis Pharmaceuticals, Inc. (IONS)
Brett Monia, Ph.D.
CEO

Silence Therapeutics, plc (SLN)
Craig Tooman
CEO

ReCode Therapeutics, Inc.
David Lockhart, Ph.D.
President and CSO

Locanabio, Inc.
Jim Burns, Ph.D.
CEO

 

2:45 p.m.

Break

3:00 p.m.

 Panel 7: Developing Genomic Medicines

Generation Bio Co.
Geoff McDonough, M.D.
President and CEO

Arbor Biotechnologies
Devyn Smith, Ph.D.
CEO

Design Therapeutics, Inc.
João Siffert, M.D.
President and CEO

Verve Therapeutics, Inc.
Sekar Kathiresan, M.D.
Co-founder and CEO

Metagenomi, Inc.
Simon Harnest
Chief Investment Officer and SVP of
Strategy

 

 

Virtual Fireside Chats

Aileron Therapeutics, Inc.
Albireo Pharma, Inc.
Alector, Inc. (invited, not confirmed)
Aravive, Inc.
Atea Pharmaceuticals, Inc.
Bellus Health, Inc.
Biohaven Pharmaceutical Holding Co. Ltd
Brickell Biotech, Inc.
Caraway Therapeutics, Inc.
Cardiff Oncology, Inc.
Chinook Therapeutics, Inc.
CRISPR Therapeutics AG
CytoImmune Therapeutics, Inc.
Entrada Therapeutics, Inc.
Elucida Oncology, Inc
Exelixis, Inc.
Geneius Biotechnology, Inc.
Icosavax, Inc.
ImmunoGen, Inc.
Inventiva S.A.
KAHR Bio
Krystal Biotech, Inc.
PhaseBio Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc.
UniQure N.V.
Vaccitech plc
Vedanta Biosciences, Inc.
Viking Therapeutics, Inc.
Viridian Therapeutics, Inc. (do not show as attending company yet)
Xenon Pharmaceuticals, Inc.